“We need #women who are so strong they can be #gentle, so #educated they can be #humble, so fierce they can be #compassionate, so #passionate they can be #rational, and so disciplined they can be #free.” ― Kavita N. Ramdas

Woke up this morning to a #ctDNA showing a deleterious #BRCA1 frameshift alteration that’s deliterious for a patient with advanced/metastatic/symptomatic #cholangiocarcinoma. Started off as an unknown primary (#CUP) & hypercalemia 🦴of malignancy with confusion🧠. Test 💯 🧬🩸🎯.

Dear #MedTwitter There is a consensus for first-line BTC: GemCis+Durva. However, the choice of second line is less clear. FOLFOX after GemCis is not always practicable. Nal-IRI in second-line is controversial because of conflicting data from NIFTY and NALIRICC. Here an overview:

🔥Great news: EMA approves Trastuzumab-Deruxtecan for #gastriccancer🔥 👉Enhertu is indicated for patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen ESMO - Eur. Oncology OncoAlert

🔥Hot off the press: Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma🔥 Journal of Hepatology doi.org/10.1016/j.jhep… ✅🌎NGS RWD 👉I promise 😇, the most granular genetic analysis on key oncogenic drivers in #CCA EASL Education #livertwitter

📰🗣️🔊‼️ Great news to start the day in #HCC! #EMA opinion out for #DurvaTreme Durvalumab in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable HCC ⁦ESMO - Eur. Oncology⁩ ⁦Grupo Español de Tratamiento de Tumores Digestivos⁩ ⁦ ema.europa.eu/en/medicines/h…

Summary of the 4 new drugs/indications that were approved for GI malignancies by FDA Oncology in 2022: - Nivo & Ipi/Nivo - Durvalumab - Futibatinib - Treme + Durva #GastricCancer #MedEd OncoAlert ASCO #GIOncology #CRCSM #MedTwitter #OncTwitter #Oncology #gism

Excited to share our paper in NatureRevClinOncol! 📚🎉 We reviewed the most common long-term and late or delayed adverse events associated w chemotherapy & other anticancer treatments Huge thanks to Nicole Kuderer, MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏 Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙 Maryam Lustberg MD, MPH, FASCO Aakash Desai, MD, MPH nature.com/articles/s4157…

New #JITC article: Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment bit.ly/3EHBdL3 Lara Donhauser Louisa Hempel

Guten Morgen mit #Ausschreibung. Wir werden eine KI-basierte Datenintegration einführen und ein Data Warehouse für die internistische Onkologie aufbauen. Für dieses Vorhaben suchen wir einen qualifizierten Technologie-Partner: aio-portal.de/aio-studien-gg… BVDW DFKI KI Bundesverband

🔥KEYNOTE-811 @ #ESMO2023 👏Great discussion by Florian Lordick 👉Major advances in gastric cancer in 2023! 😅Biomarker driven...Her2, PDL-1, Claudin 18.2, FGFR2 ❗️Don't miss: 👉the KM curve in PDL-1 neg cohort 👉Update of the ESMO gastric living guideline! ESMO - Eur. Oncology

Historical moment for GU oncology. Tom Powles brilliantly presents the results of the EV-302 phase 3 trial, showing a doubling of OS for patients with mUC receiving 1L enfortumab vedotin+pembro vs SoC platinum-based chemo. ADCs keep shining and improving outcomes! #ESMO23

Please read our new paper, published today with Springer Nature in npj Journals, on the practical approach at NCT Heidelberg and Nationales Centrum für Tumorerkrankungen Dresden to clinical decision-making in molecular tumor boards based on genome/exome, transcriptome, and methylome data: rdcu.be/dpwCy

It is back! Immunoctobefest…… Once again, Dietmar and Ben assemble an amazing speaker list covering all angles of T cell biology🫡 See you in Munich physio.wzw.tum.de/en/symposia/sy…

Join us for the 2024 ImmunOctoberfest meeting! 🍺🔬 Registration for the event is now open at: immunoctoberfest.de

!!! PAPER OUT in EMBO Mol. Medicine !!! #TP53-mutant #AML is notoriously hard to treat. Immunotherapies might be a promising therapeutic option. Ever wondered what the impact of the #TP53-mutational status on #CARTCell efficacy in AML is? doi.org/10.1038/s44321… A 🧵1/n

As #ASCO24 ASCO approaches, we wanted to invite our colleagues to a healthy🏃‍♂️alternative in Chicago 🏙️ The #OncoAlertASCO5k 🚨is back and OncoAlert would like to invite anyone who would like to participate to do so. Where and When: Saturday June 1st, 2024 at 7AM (local

The #OncoAlert5k 🚨 at #ESMO24 Barcelona🇪🇸 REGISTRATION NOW OPEN oncoalert.m-pages.com/8e4BL2/the-onc… Dear Colleagues, Warm invitation to join the OncoAlert Network and friends to this 5k in Barcelona on Saturday September 14, 2024 at 7am. The Run starts at Plaça de Catalunya, follows down

The best of the T-cell immunology in September in Munich 🍻🍺!!

💫🌟"Ready to run at the #OncoAlert5k in Barcelona during #ESMO24? 🏃‍♂️🏃‍♀️ Let’s make this an epic race for oncology! 🎽🔔🌟💫 #OncoAlertAF OncoAlert Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Jose Fernando Moura, PhD Elisa Agostinetto Yakup Ergün Elisabetta Bonzano MD, PhD Bárbara Melão, MD